Phase I Additional Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Anlotinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Soft tissue sarcoma; Thyroid cancer
- Focus Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 09 Nov 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 09 Nov 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
- 13 Jul 2016 New trial record